The present invention relates to N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides of the formula I, wherein Ar, n, X, Z, R1, R2 and R3 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase(SGK), in particular of serum and glucocorticoid regulated kinase isoform 1(SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.本發明係有關一種式I之N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺□其中Ar、n、X、Z、R1、R2與R3具有如申請專利範圍中指示之定義。式I化合物為有價值之藥理活性化合物，其可調控蛋白質激酶活性，明確言之血清與糖皮質激素調節激酶(SGK)(特定言之血清與糖皮質激素調節激酶同型1(SGK-1，SGK1))之活性，且適合治療其中SGK活性不適當之疾病，例如：退化性關節病變或發炎過程，如：骨關節炎或風濕症。本發明進一步有關製備式I化合物之方法、其作為醫藥之用途、及含其之醫藥組成物。
